An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)

International Journal of Hematology

Volumn 95, Issue 6, 2012, Pages 652-659

  Shirasugi, Yukari ^a   Ando, Kiyoshi ^a   Miyazaki, Koji ^b   Tomiyama, Yoshiaki ^c   Iwato, Koji ^d   Okamoto, Shinichiro ^e   Kurokawa, Mineo ^f   Kirito, Keita ^g   Hashino, Satoshi ^h   Ninomiya, Haruhiko ⁱ   Mori, Shinichiro ^j   Yonemura, Yuji ^k   Usuki, Kensuke ^l   Wei, Helen ^m   Lizambri, Richard ^m  

^a TOKAI UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

^d ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^e KEIO UNIVERSITY HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^g YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^h HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

ⁱ UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^j KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^k KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^l Kanto Medical Center   (Japan)

^m AMGEN INC   (United States)

more..

Author keywords

Immune thrombocytopenic purpura (ITP); Romiplostim; Thrombopoietin mimetic; Thrombopoietin receptor agonists

Indexed keywords

ROMIPLOSTIM;

ADULT; AGED; ANEMIA; APPENDICITIS; ARTICLE; BACKACHE; BLOOD TRANSFUSION REACTION; CLINICAL ARTICLE; COMPRESSION FRACTURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EPISTAXIS; FEMALE; GRAND MAL SEIZURE; HEMATOMA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRACRANIAL ANEURYSM; JAPANESE; MALAISE; MALE; MELENA; OPEN STUDY; ORAL BLEEDING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SPINE FRACTURE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VERTEBRAL CANAL STENOSIS; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84864982009     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1065-2     Document Type: Article

References (34)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-93.
2. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113: 6511-21.
3. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146: 585-96.
4. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44:S3-11. (Pubitemid 350256798)
5. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol. 2010;150:9-20.
6. Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81:162-8. (Pubitemid 40270991)
7. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329-35.
8. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2009;115:168-86.
9. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117: 4190-207.
10. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94:850-6.
11. Arnold DM, Stasi R. Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H pylori infection? ASH evidence-based review. Hematology Am Soc Hematol Educ Program. 2008;2008:31-2.
12. Kuwana M, Ikeda Y. Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. Int J Hematol. 2006;84:309-15. (Pubitemid 46606571)
13. Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol. 2005;100: 1265-70. (Pubitemid 40904347)
14. Tsumoto C, Tominaga K, Okazaki H, Tanigawa T, Yamagami H, Watanabe K, et al. Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol. 2009;88:789-93.
15. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997;126:307-14. (Pubitemid 27078779)
16. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79:504-22. (Pubitemid 38401771)
17. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002;100:728-30. (Pubitemid 34761148)
18. Rank A, Weigert O, Ostermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics. 2010;4:139-45.
19. Nplate (romiplostim), European Public Assessment Report summary. 2009.
20. Nplate TM (romiplostim) Prescribing Information. Amgen, Inc., Thousand Oaks, CA. 2011.
21. Nplate TM (romiplostim) Prescribing Information. European Medicines Agency. Amgen, Inc., Thousand Oaks, CA. 2011.
22. Romiplate prescribing information. 2011; http://www.mhlw.go.jp/stf/ shingi/2r985200000136yg-att/2r9852000001372i.pdf.
23. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94:1-26.
24. Matthews HW. Racial, ethnic and gender differences in response to medicines. Drug Metabol Drug Interact. 1995;12:77-91.
25. Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol. 2007;47:1489-97. (Pubitemid 350115297)
26. Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;90:157-65.
27. Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a doubleblind, randomized Phase III clinical trial. Int J Hematol. 2011;94: 71-80.
28. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet. 2008;371:395-403. (Pubitemid 351181334)
29. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007;321:1-18. (Pubitemid 46454303)
30. Mason S, La S, Mytych D, Swanson SJ, Ferbas J. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin. 2003;19:651-9. (Pubitemid 37288073)
31. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289:1-16. (Pubitemid 38900899)
32. Kuter DJ, Bussel JB, Newland A, Wasser JS, Lyons RM, George JN, et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study. ASH Annu Meet Abstr. 2010;116:68.
33. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113: 161-71.
34. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889-99.